Cargando…
Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are first-line drugs for lung cancers with activating EGFR mutations. Although first- and second-generation EGFR-TKIs were standard first-line treatments, acquired resistance (AR) to these drugs is almost inevitable. Cell line...
Autores principales: | Ohara, Shuta, Suda, Kenichi, Mitsudomi, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915563/ https://www.ncbi.nlm.nih.gov/pubmed/33572269 http://dx.doi.org/10.3390/cells10020354 |
Ejemplares similares
-
Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib
por: Mizuuchi, Hiroshi, et al.
Publicado: (2015) -
Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
por: Koga, Takamasa, et al.
Publicado: (2021) -
Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance
por: Nishino, Masaya, et al.
Publicado: (2021) -
Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
por: Suda, Kenichi, et al.
Publicado: (2015) -
TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)